Arbutus Biopharma Corp (ABUS)
Nasdaq · Pharmaceutical Preparations · Inc. A1
What they're doing
Between 2026-07-12 and 2026-10-10, public records show 1 signal for Arbutus Biopharma Corp. Most notable: 2026-07-16: Filed 8-K disclosing director or officer change. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-10-10 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing material agreement
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-10-01 | Androski Lindsay | director | D | 24,655 | 5 | $123,275 |
| 2026-10-01 | Sawhney Roger | director | D | 17,142 | 5 | $85,710 |
| 2026-10-01 | Nguyen Tuan | officer | D | 48,081 | 5 | $240,405 |
| 2026-10-01 | Beardsley Robert A | director | D | 17,948 | 5 | $89,740 |
| 2026-10-01 | Roivant Sciences Ltd. | director | D | 8,967,383 | 5 | $44,836,915 |
| 2026-09-18 | Beardsley Robert A | director | F | 99,057 | 5.07 | $502,219 |
| 2026-09-18 | Beardsley Robert A | director | M | 78,800 | 4.24 | $334,112 |
| 2026-09-18 | Beardsley Robert A | director | M | 52,533 | 3.2 | $168,106 |
| 2026-09-18 | Sawhney Roger | director | F | 100,508 | 5.07 | $509,576 |
| 2026-09-18 | Sawhney Roger | director | M | 78,800 | 4.24 | $334,112 |
| 2026-09-18 | Sawhney Roger | director | M | 52,533 | 3.34 | $175,460 |
| 2026-09-18 | Nguyen Tuan | officer | F | 206,637 | 5.07 | $1,047,650 |
| 2026-09-18 | Nguyen Tuan | officer | M | 27,475 | 4.39 | $120,615 |
| 2026-09-18 | Nguyen Tuan | officer | M | 265,625 | 3.49 | $927,031 |
| 2026-09-18 | Androski Lindsay | director | F | 82,527 | 5.07 | $418,412 |
| 2026-09-18 | Androski Lindsay | director | M | 10,456 | 4.39 | $45,902 |
| 2026-09-18 | Androski Lindsay | director | M | 116,408 | 3.2 | $372,506 |
| 2026-02-02 | Nguyen Tuan | officer | A | 73,500 | 0 | $0 |
| 2026-02-02 | Androski Lindsay | director | A | 28,000 | 0 | $0 |
| 2025-02-14 | Naftzger J. Christopher | officer | A | 54,300 | 0 | $0 |
| 2025-02-14 | McElhaugh Michael J. | director | A | 177,000 | 0 | $0 |
| 2025-02-14 | HASTINGS DAVID C | officer | A | 90,100 | 0 | $0 |
| 2025-02-14 | Sims Karen | officer | A | 49,300 | 0 | $0 |
| 2025-02-04 | HASTINGS DAVID C | officer | S | 22,183 | 3.28 | $72,760 |
| 2025-02-04 | Sims Karen | officer | S | 19,348 | 3.28 | $63,461 |
| 2025-02-04 | McElhaugh Michael J. | director | S | 23,790 | 3.28 | $78,031 |
| 2025-02-04 | Naftzger J. Christopher | officer | S | 11,333 | 3.28 | $37,172 |
| 2024-08-14 | MANCHESTER KEITH S | director | S | 8,846 | 3.69 | $32,642 |
| 2024-08-14 | MANCHESTER KEITH S | director | M | 54,915 | 0.56 | $30,752 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
7-day average 10 views/day vs 90-day median 9.
Recent filings
- 2026-10-22 8-K
- 2026-10-07 4
- 2026-10-07 4
- 2026-10-07 4
- 2026-10-07 4
- 2026-10-07 SCHEDULE 13G/A
- 2026-10-05 4
- 2026-10-05 SCHEDULE 13D/A
- 2026-10-01 SC TO-I/A
- 2026-09-30 SC TO-I/A
- 2026-09-23 4
- 2026-09-23 4
- 2026-09-23 4
- 2026-09-23 4
- 2026-09-04 SCHEDULE 13G
- 2026-08-24 SC TO-I
- 2026-08-21 SC TO-C
- 2026-08-21 8-K
- 2026-08-12 SCHEDULE 13G/A
- 2026-08-12 10-Q